Search

Displaying results 3621 - 3630 of 6076 in total
  1. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

  2. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  3. Drug

    Birinapant

    go.drugbank.com/drugs/DB11782
    Investigational

    Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

  4. Drug

    Rivenprost

    go.drugbank.com/drugs/DB16315
    Investigational

    Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).

  5. Drug

    JTC-801 free base

    go.drugbank.com/drugs/DB17033
    Experimental

    An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]

  6. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  7. Drug

    ART5803

    go.drugbank.com/drugs/DB18379
    Investigational

    ART5803 is a humanized one-armed monoclonal antibody with a high affinity for the NMDA receptor.

  8. Drug

    Rugonersen

    go.drugbank.com/drugs/DB18662
    Investigational

    Rugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.

  9. Drug

    IMT-288

    go.drugbank.com/drugs/DB19068
    Investigational

    IMT-288 is under investigation in clinical trial NCT01730638 (Immunotep for Patients With Medullary Thyroid Carcinoma.).

  10. Drug

    Ensovibep

    go.drugbank.com/drugs/DB19078
    Investigational

    Ensovibep is under investigation in clinical trial NCT04501978 (ACTIV-3: Therapeutics for Inpatients With COVID-19).